Publicacions en col·laboració amb investigadors/ores de King's College London (43)

2024

  1. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis

    Schizophrenia bulletin, Vol. 50, Núm. 3, pp. 496-512

  2. Cognitive remediation therapy to enhance cognition and improve recovery in early psychosis: the ECLIPSE research programme including an RCT

    Programme Grants for Applied Research, Vol. 12, Núm. 4

  3. Development of the PSYCHS: Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPS

    Early Intervention in Psychiatry, Vol. 18, Núm. 4, pp. 255-272

  4. Effects of cannabidiol on symptoms in people at clinical high risk for psychosis

    World Psychiatry

  5. Increased hippocampal blood flow in people at clinical high risk for psychosis and effects of cannabidiol

    Psychological Medicine, Vol. 54, Núm. 5, pp. 993-1003

  6. Understanding the Mechanisms of Cognitive Remediation on Recovery in People With Early Psychosis: A Mediation and Moderation Analysis

    Schizophrenia bulletin, Vol. 50, Núm. 6, pp. 1371-1381

2023

  1. Cognitive Remediation Works But How Should We Provide It? An Adaptive Randomized Controlled Trial of Delivery Methods Using a Patient Nominated Recovery Outcome in First-Episode Participants

    Schizophrenia bulletin, Vol. 49, Núm. 3, pp. 614-625

  2. Hippocampal Glutamate, Resting Perfusion and the Effects of Cannabidiol in Psychosis Risk

    Schizophrenia Bulletin Open, Vol. 4, Núm. 1

  3. Satisfaction with cognitive remediation therapy: its effects on implementation and outcomes using the cognitive remediation satisfaction scale

    Schizophrenia, Vol. 9, Núm. 1

  4. What interventions should we implement in England's mental health services? The mental health implementation network (MHIN) mixed-methods approach to rapid prioritisation

    Frontiers in Health Services, Vol. 3

2022

  1. Altered relationship between cortisol response to social stress and mediotemporal function during fear processing in people at clinical high risk for psychosis: a preliminary report

    European Archives of Psychiatry and Clinical Neuroscience, Vol. 272, Núm. 3, pp. 461-475

  2. Determinants of patient-reported outcome trajectories and symptomatic recovery in Improving Access to Psychological Therapies (IAPT) services

    Psychological Medicine, Vol. 52, Núm. 14, pp. 3231-3240

  3. The Relationship Between Grey Matter Volume and Clinical and Functional Outcomes in People at Clinical High Risk for Psychosis

    Schizophrenia Bulletin Open, Vol. 3, Núm. 1

  4. Treating common mental disorder including psychotic experiences in the primary care improving access to psychological therapies programme (the TYPPEX study): protocol for a stepped wedge cluster randomised controlled trial with nested economic and process evaluation of a training package for therapists

    BMJ open, Vol. 12, Núm. 6, pp. e056355

2021

  1. Adverse clinical outcomes in people at clinical high-risk for psychosis related to altered interactions between hippocampal activity and glutamatergic function

    Translational Psychiatry, Vol. 11, Núm. 1

  2. Correction: Adverse clinical outcomes in people at clinical high-risk for psychosis related to altered interactions between hippocampal activity and glutamatergic function (Translational Psychiatry, (2021), 11, 1, (579), 10.1038/s41398-021-01705-z)

    Translational Psychiatry

  3. Counterpoint. Early intervention for psychosis risk syndromes: Minimizing risk and maximizing benefit

    Schizophrenia Research, Vol. 227, pp. 10-17

  4. Development and external validation of the Psychosis Metabolic Risk Calculator (PsyMetRiC): a cardiometabolic risk prediction algorithm for young people with psychosis

    The Lancet Psychiatry, Vol. 8, Núm. 7, pp. 589-598

  5. Integrated metastate functional connectivity networks predict change in symptom severity in clinical high risk for psychosis

    Human Brain Mapping, Vol. 42, Núm. 2, pp. 439-451

  6. Interactions between hippocampal activity and striatal dopamine in people at clinical high risk for psychosis: relationship to adverse outcomes

    Neuropsychopharmacology, Vol. 46, Núm. 8, pp. 1468-1474